Dr. M. Michelle Berrey joined Chimerix in 2012 as Chief Medical Officer (CMO) and was named President and Chief Executive Officer (CEO) in April 2014. Prior to joining Chimerix, Dr. Berrey was CMO at Pharmasset, Inc., a company that focused on the development of nucleotide analogs for the treatment of hepatitis C, from 2007 until its acquisition by Gilead Sciences, Inc. (NASDAQ: GILD) in January 2012. Dr. Berrey's expertise includes the design, early development, medical governance, clinical strategy and product life cycle management of antiviral compounds. Previously, Dr. Berrey served as Vice President, Viral Diseases, Clinical Pharmacology & Discovery Medicine at GlaxoSmithKline, where she was responsible for the early development of compounds for the treatment of HIV, hepatitis viruses and hepatic fibrosis. Dr. Berrey received her MD from the Medical College of Georgia and a Master of Public Health from Emory University. She completed her internship and residency in Internal Medicine at the University of North Carolina at Chapel Hill, and was a Senior Fellow in Infectious Diseases at the University of Washington, Seattle, where she conducted research in HIV transmission and acute HIV infection. She is Board Certified in Internal Medicine and Infectious Diseases.
Dr. Nichols joined Chimerix as Chief Medical Officer, in September 2014, from ViiV Healthcare, where he was the Head of Global Development; prior to his tenure at ViiV, Dr. Nichols spent ten years at GlaxoSmithKline leading multiple global antiviral programs in the United States and Europe, including the development and regulatory submissions to the FDA and EMA for the approval of Tivicay and the recent FDA approval of Triumeq. Dr. Nichols spent four years on the faculty of the Fred Hutchinson Cancer Research Center in Seattle, WA, where he was the principal investigator on NIH-funded grants exploring the prevention and treatment of CMV and respiratory virus infections in HCT recipients. Dr. Nichols received his M.D. from Duke University and earned an M.S. in Epidemiology from the University of Washington, where he completed a Fellowship in Infectious Diseases.
Mr. Trost joined Chimerix in 2011 as Senior Vice President and Chief Financial Officer, and had been working with Chimerix since 2010 in a consulting capacity related to the Series F financing and the BARDA contract. With more than 30 years of experience in the financial field, Mr. Trost last served as Vice President and CFO at Argos Therapeutics, Inc. (NASDAQ: ARGS), a venture-backed immunotherapy company located in Research Triangle Park. Previously, he was Senior Vice President and CFO at InteCardia, Inc., a venture-backed cardiac imaging company. While at InteCardia, Mr. Trost played a key role in negotiating and executing the sale of the company to Syncor International Corporation (NASDAQ: SCOR). Prior to InteCardia, Mr. Trost served as Executive Vice President and CFO of Coastal Physician Group, Inc. (NYSE: DR), a contract provider of emergency room physicians, having joined the company as Vice President of Corporate Development. Previously, he held the position of Vice President of Finance at Morganite North America. Mr. Trost began his professional career with PricewaterhouseCoopers LLP, spending time in four offices over 12 years, including an international assignment, and last served as a Senior Manager in the Research Triangle practice. Mr. Trost holds a BS in Accounting from the University of Illinois at Urbana-Champaign and is a Certified Public Accountant.
Ms. Richardson has over 25 years of pharmaceutical industry experience, with a strong background in launching new products and developing new therapeutic areas. Her category experience includes work in diabetes, anaphylaxis, cardiovascular, respiratory, lipids and neurology. Ms. Richardson joined Chimerix in January 2014 as Chief Commercial Officer, in charge of building and leading the organization’s commercial structure. Prior to that, Ms. Richardson was the Vice President and Head of the Global lixisenatide franchise, leading the commercial worldwide launch of Lyxumia. She also held the position of Vice President of Marketing at Reliant Pharmaceuticals, overseeing marketing and market research functions, including the successful launch of the first prescription omega-3 product, which helped lead to the company's acquisition by GlaxoSmithKline. Ms. Richardson held various positions of increasing responsibility at GlaxoSmithKline in the sales, market research, and marketing functions, working on several launches. Ms. Richardson served on the Board of Directors of Healthy Women, a non-profit organization dedicated to promoting health and wellness among women. In 2008, she was nominated by her peers as one of the "100 Most Inspiring Leaders" in the Life Sciences field and labeled as a "Market Maker" in PharmaVoice magazine, and in 2011 she was given the "Rising Star" award by the Healthcare Businesswomen's Association. She earned her BA in English at the University of Pennsylvania.
Dr. Alrutz joined Chimerix in 2012 and in September 2014 he was named Vice President, General Counsel. From 2002 to 2011, Dr. Alrutz was counsel to Trimeris, Inc. (NASDAQ: TRMS) serving in a variety of in-house positions, most recently as General Counsel. While at Trimeris, Dr. Alrutz had primary responsibility and oversight of the company’s legal department during the development and commercialization of FUZEON®, a first-in-class viral fusion inhibitor for the treatment of HIV. Dr. Alrutz received his JD from Duke University School of Law and his PhD in molecular biology from the Tufts University, Sackler School of Biomedical Sciences. He received his B.A. from the University of Pennsylvania
Prior to joining Chimerix in 2007, Dr. Lanier contributed to the HIV and cancer programs at Burroughs Wellcome, GlaxoWellcome and GlaxoSmithkline where he supervised a clinical virology/ immunology laboratory, led teams for drug discovery and was involved in preclinical and clinical development (3 approved NDAs), product differentiation, post-marketing support and licensing opportunity evaluation. Dr. Lanier has over 20 years of experience in the discovery and development of antivirals; he has focused much of his career on understanding the activity, mechanism, and resistance profiles of nucleoside analogs used for prevention and treatment of viral disease caused by HIV, CMV, adenovirus, and poxviruses. He holds a BA degree in Biology from New College and a PhD in Cellular and Molecular Biology from the University of Texas Health Science Center in San Antonio.
Dr. Mozaffari joined Chimerix as Vice President of Market Access and Reimbursement in September 2014. He brings over 20 years of experience in the healthcare industry, focused on integrating medical, marketing, and market access disciplines. His expertise in understanding complex reimbursement issues around the globe will be instrumental to securing broad access for brincidofovir and future compounds. Dr. Mozaffari joins Chimerix from Sanofi, where he most recently served as Senior Director, Global Diabetes Market Access, Global Diabetes Commercial Operations. Preceding that role he was the Senior Director of Evidence Based Medicine for US Medical Affairs from 2005 to 2011. Prior to joining Sanofi, Dr. Mozaffari was Director, Therapeutic Area Lead Cardiovascular Worldwide Outcomes Research, Global Medical Affairs at Pfizer, and Senior Associate Director, Global Health Outcomes at Pharmacia Corporation. Dr. Mozaffari received his PharmD from the University of California at San Francisco, his Master of Public Health from the University of Washington, and an MBA from Rutgers University.
Dr. Odin Naderer Joined Chimerix as Vice President of Clinical Pharmacology and Translational Medicine. He brings over 15 years of clinical pharmacology and development leadership experience in the area of infectious diseases. Dr. Naderer joins Chimerix from GlaxoSmithKline where he served most recently as Medicine Development Leader and Senior Scientific Director, Infectious Diseases. He previously served as Clinical Pharmacologist in the Antiviral Clinical Pharmacology/Discovery Medicine and Senior Clinical Research Scientist in HIV and Opportunistic Infections. Dr. Naderer has also served most recently as the EFPIA Coordinator for the IMI funded New Drugs for Bad Bugs Clinical Trial Consortium (COMBACTE) that is being developed in Europe. Dr. Naderer earned a BS in Nutrition and Medical Dietetics and his PharmD at the University of Illinois at Chicago.
Dr. Vargas-Cortes joined Chimerix as Vice President of Program Management in June of 2015. He brings over 20 years of experience in clinical development, clinical operations and project management in several therapeutic areas including infectious diseases, immunology, inflammation and oncology. Prior to Chimerix, he held the positions of Global Head, PD-L1 Clinical Operations and Global Head, Early Stage Clinical Operations at EMD Serono in Massachusetts. He served as Program Leader for early stage inflammation programs at Roche, and before that he was responsible for the development of Incivek (telaprevir) for hepatitis C in the capacity of franchise and program lead at Vertex Pharmaceuticals. Previously, Dr. Vargas-Cortes was at Eli Lilly, Medimmune and GlaxoSmithKline, where he led the global development, registration and life-cycle management of Valtrex (valacyclovir) for herpes infections. Dr. Vargas-Cortes earned B.Sc. degrees in biology and in microbiology from the University of Los Andes, Bogota, Colombia and his Ph.D. in Immunology from the University of Stockholm in Sweden and completed his post-doctoral training at the University of Massachusetts in Worcester, MA
Dr. Ware joined Chimerix in 2007 and in January 2015 was named Vice President, Chemistry. Prior to joining Chimerix, he worked at PharmaCore, Inc. and served in a consulting capacity at Scynexis, Inc., in the areas of chemical process development and cGMP synthesis. Dr. Ware also contributed to preclinical oncology and malaria programs at Serenex, Inc. where he led a team of medicinal chemists. Dr. Ware worked in the area of drug addiction therapy as a postdoctoral researcher at the Research Triangle Institute International under the direction of Dr. F. Ivy Carroll. He received his PhD in Chemistry from Wake Forest University, MBA from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill, and BA in Chemistry from the University of North Carolina at Greensboro.